logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

Gilead Sciences News Results from Phase 2/3 CAPELLA trial evaluating Gilead Sciences ( GILD )  lenacapavir achieved the primary endpoint in heavily treatment-experienced people with multidrug-resistant HIV-1 infection. The study showed that 88% of participants receiving lenacapavir experienced at least...

Read More

November 19, 2020

0

Anixa Biosciences: Why This Firm Outperformed Today

Anixa Biosciences Outperformance Anixa Biosciences Inc ( ANIX ) is the worldwide licensee of a patent technology titled "Ovarian Cancer Vaccine" which was created at Cleveland Clinic. Anixa Therapeutics specializes in the treatment and prevention of cancer and infectious diseases....

Read More

March 12, 2021

0

Let the Market Plummet But Not Our stocks

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally. Currently, during the strong economic conditions, commentators attribute...

Read More

December 3, 2019

0

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

Gilead Sciences and Merck Announced Agreement for Long-Term HIV Combination Treatment Gilead Sciences ( GILD ) and Merck ( MRK ) announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s...

Read More

March 15, 2021

0

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.  

AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19  AstraZeneca ( AZN ) has modified an existing agreement with the U.S. Government to supply up to 500,000 additional doses of AZD7442 - a long-acting antibody ( LAAB...

Read More

March 17, 2021

0

CureVac Has Very Interesting Future Plans

CureVac CureVac B.V. ( CVAC ) is a global biopharmaceutical company specializing in messenger RNA ( mRNA ) technology. The firm has more than 20 years of expertise in developing and optimizing versatile biological molecules for prevention and treatment purposes....

Read More

March 22, 2021

0

About the Prohost Portfolio Tables

Firstly, Forty-Seven and IVERIC bio  We remind that the two condemned stocks  Forty-Seven ( FTSV ) and   IVERIC bio ( ISEE ) have continued to outperform since the day they managed to prove their lead products' safety and efficacy...

Read More

December 5, 2019

0

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington's Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

Negative News from Ionis Pharmaceuticals  Ionis Pharmaceuticals ( IONS ) announced that its partner, Roche ( RHHBY ) , has decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen for Huntington's disease (HD). A pre-planned review...

Read More

March 23, 2021

0

The US FDA Approved Alnylam's OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

Alnylam Announces FDA Approval o f OXLUMO™ Injection for PH1 Alnylam ( ALNY ) announced that the US FDA has approved its subcutaneous OXLUMO™ (lumasiran) injection, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 ( PH1...

Read More

November 24, 2020

0

Nektar at the 61st American Society of Hematology (ASH) Meeting

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ ( NKTR ) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology ( ASH ) Annual Meeting & Exposition have been promising. Positive data presented from Fred Hutchinson...

Read More

December 11, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 107
  • 108
  • 109
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy